ARTICLE | Company News
Astralis autoimmune, dermatology news
October 16, 2006 7:00 AM UTC
ASTR said it will discontinue its drug development activities and is considering strategic alternatives, including selling its assets. In August, the company said its liabilities had exceeded its cash...